424
Participants
Start Date
May 17, 2016
Primary Completion Date
August 3, 2017
Study Completion Date
August 3, 2017
Evolocumab
Administered by subcutaneous injection with an automated mini doser
Placebo to Evolocumab
Administered by subcutaneous injection with an automated mini doser
Research Site, Edegem
Research Site, Leuven
Research Site, Liège
Research Site, New York
Research Site, New York
Research Site, New Windsor
Research Site, Granada
Research Site, Wilmington
Research Site, Salisbury
Research Site, Suffolk
Research Site, Shelby
Research Site, Tabor City
Research Site, Dunwoody
Research Site, Chihuahua City
Research Site, Fleming Island
Research Site, Daytona Beach
Research Site, Jacksonville
Research Site, Hollywood
Research Site, Coral Gables
Research Site, Miami
Research Site, Miami
Research Site, West Palm Beach
Research Site, Boca Raton
Research Site, Inverness
Research Site, Tuscumbia
Research Site, Verona
Research Site, Tupelo
Research Site, Louisville
Research Site, Columbus
Research Site, Guadalajara
Research Site, Bay City
Research Site, Chicago
Research Site, Chicago
Research Site, Chicago
Research Site, Norman
Research Site, Houston
Research Site, Austin
Research Site, Lakewood
Research Site, Denver
Research Site, Meridian
Research Site, Phoenix
Research Site, Albuquerque
Research Site, Las Vegas
Research Site, Los Angeles
Research Site, Lomita
Research Site, Tarzana
Research Site, Spring Valley
Research Site, San Ramon
Research Site, Walnut Creek
Research Site, Roseville
Research Site, Auburn
Research Site, Scarborough
Research Site, Methuen
Research Site, Vancouver
Research Site, Gatineau
Research Site, Montreal
Research Site, Saint-Jérôme
Research Site, Roma
Research Site, Roma
Research Site, Katowice
Research Site, Krakow
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Almería
Research Site, Badalona
Research Site, Barcelona
Lead Sponsor
Amgen
INDUSTRY